
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : APT-1011
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
24-Week Induction Study of APT-1011 in Adult Subjects with Eosinophilic Esophagitis (EoE) (FLUTE 3)
Details : APT-1011 is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Eosinophilic Esophagitis.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
December 02, 2022
Lead Product(s) : APT-1011
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : APT-1011
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access Protocol for Patients With Eosinophilic Esophagitis
Details : APT-1011 is a Steroid drug candidate, which is currently being evaluated in clinical studies for the treatment of Eosinophilic Esophagitis.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
October 27, 2021
Lead Product(s) : APT-1011
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : APT-1011
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : APT-1011 is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Eosinophilic Esophagitis.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
October 19, 2021
Lead Product(s) : APT-1011
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : All APT-1011 dose arms showed clinically meaningful and statistically significant achievement of histological remission with reduction of eosinophil counts in the esophageal mucosa, compared to placebo, at 12 weeks.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
October 27, 2020
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : TPG Capital IP
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ellodi Pharmaceuticals is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare).
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
September 22, 2020
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : TPG Capital IP
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : APT-1011
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)
Details : APT-1011 is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Eosinophilic Esophagitis.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
February 24, 2020
Lead Product(s) : APT-1011
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
